1
|
Wang D, Zhang Y, Ma C, Ma D, Zhao Q, Wang F, Huang Y, Li J, Zhang L, Zhou EM. Live recombinant Lactococcuslactis expressing avian hepatitis virus ORF2 protein: Immunoprotection against homologous virus challenge in chickens. Vaccine 2018; 36:1108-1115. [PMID: 29406242 DOI: 10.1016/j.vaccine.2018.01.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 12/22/2017] [Accepted: 01/04/2018] [Indexed: 12/26/2022]
Abstract
Avian hepatitis E virus (aHEV) is a pathogen associated with hepatitis-splenomegaly syndrome in chickens. To date, no commercial vaccine is available for preventing aHEV infection. In this study, three recombinant LactococcuslactisNZ9000experimental live vaccines expressing cytoplasmic, secreted, and cell wall-anchored forms of aHEV truncated ORF2 protein spanning amino acids 249-606 (ΔORF2) were constructed using pTX8048 vector and characterized. Each chicken was immunized three times at two-week intervals with one of the three live aHEV ORF2 vaccines (experimental group) or with live vaccine containing empty vector only (control group). Both groups were then challenged with aHEV and evaluated to compare immune responses and immunogenic effects. Serum IgG levels, secretory IgA (sIgA) levels in bile and jejunal lavage fluid, and mRNA expression levels ofIL-2 and IFN-γ in liver and spleen were significantly higher in experimental chickens than in controls. Meanwhile, post-challenge serum and fecal virus loads were significantly lower in experimental chickens versus controls. Moreover, on day 7 post infection (PI), serum lactose dehydrogenase (LDH) levels were significantly higher in controls than experimental chickens. Furthermore, at day 28 PI, obvious gross pathological lesions and histopathological changes typical for aHEV infection were observed in control livers and spleens, with only moderate pathological changes observed in the experimental group. The results of this study collectively demonstrate that an oral vaccineusing L.lactisNZ9000 as a delivery vector for aHEV immunogenic antigen could effectively control aHEV infection of chickens.
Collapse
Affiliation(s)
- Dian Wang
- College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, Heilongjiang, PR China; Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Harbin 150030, Heilongjiang, PR China
| | - Yue Zhang
- College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, Heilongjiang, PR China; Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Harbin 150030, Heilongjiang, PR China
| | - Chunli Ma
- Food College, Northeast Agricultural University, Harbin 150030, Heilongjiang, PR China
| | - Dexing Ma
- College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, Heilongjiang, PR China; Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Harbin 150030, Heilongjiang, PR China.
| | - Qin Zhao
- Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Northwest A&F University, Yangling 712100, Shanxi, PR China
| | - Fen Wang
- College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, Heilongjiang, PR China; Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Harbin 150030, Heilongjiang, PR China
| | - Yuchen Huang
- College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, Heilongjiang, PR China; Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Harbin 150030, Heilongjiang, PR China
| | - Jian Li
- College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, Heilongjiang, PR China; Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Harbin 150030, Heilongjiang, PR China
| | - Lili Zhang
- College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, Heilongjiang, PR China; Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Harbin 150030, Heilongjiang, PR China
| | - En-Min Zhou
- Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Northwest A&F University, Yangling 712100, Shanxi, PR China.
| |
Collapse
|
2
|
Roh JH, Kang M. Live attenuated duck hepatitis virus vaccine in breeder ducks: Protective efficacy and kinetics of maternally derived antibodies. Vet Microbiol 2018; 219:107-112. [PMID: 29778181 DOI: 10.1016/j.vetmic.2018.04.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Revised: 04/09/2018] [Accepted: 04/12/2018] [Indexed: 11/18/2022]
Abstract
Duck viral hepatitis type I is a rapidly spreading infection lethal in young ducklings, caused by the duck hepatitis A virus (DHAV). Vaccination of breeder ducks is a common practice to control DHAV. However, maintaining proper maternal antibody levels in large flocks is difficult. Therefore, a simple vaccination strategy that can induces stable high antibody levels through mass vaccination is desirable. We evaluated a DHAV vaccination strategy for breeder ducks involving oral administration under field conditions, and examined the kinetics of antibody response in the ducks and their progeny. The strategy included a primary intramuscular vaccination, followed by secondary and tertiary oral vaccinations. Five weeks after the primary vaccination, virus-neutralizing antibody titers increased by 8.4 ± 1.3 log2. The titers remained stable at around 9.0 ± 1.1 log2 for up to 36 weeks. None of the progeny died when challenged with virulent DHAV at 1, 7 or 14 days of age. The transfer percentage of antibodies from the breeder ducks to their progeny was 12.8 ± 3.0%. When antibody levels of the progeny were measured from the day of hatching to 20 days of age, the levels steadily declined, reaching a mean titer of 0 log2 at 20 days. The half-life of the maternally derived antibodies against DHAV was 3.4 ± 1.1 days. Our vaccination strategy might be effective in breeder ducks because it can be easily applied and induced strong immunity. Moreover, our results might provide a foundation for the mechanistic study of maternally derived antibodies in passive protection.
Collapse
MESH Headings
- Animals
- Antibodies, Neutralizing/immunology
- Antibodies, Viral/blood
- Hepatitis Virus, Duck/immunology
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Animal/virology
- Immunity, Maternally-Acquired
- Kinetics
- Poultry Diseases/immunology
- Poultry Diseases/prevention & control
- Poultry Diseases/virology
- Vaccination/methods
- Vaccines/administration & dosage
- Vaccines/immunology
- Vaccines, Attenuated/administration & dosage
- Vaccines, Attenuated/immunology
- Viral Hepatitis Vaccines/administration & dosage
- Viral Hepatitis Vaccines/immunology
Collapse
Affiliation(s)
- Jae-Hee Roh
- Department of Veterinary Infectious Diseases and Avian Diseases, College of Veterinary Medicine and Center for Poultry Diseases Control, Chonbuk National University, South Korea
| | - Min Kang
- Department of Veterinary Infectious Diseases and Avian Diseases, College of Veterinary Medicine and Center for Poultry Diseases Control, Chonbuk National University, South Korea.
| |
Collapse
|
3
|
Abstract
Transmission of viral infection by tumour lines or other biological materials may have confounding effects on research. Many research organizations require screening for viral agents of all cell lines, tumours, sera and other biologicals before implantation or inoculation into animal models. Screening for viral contamination is done by the mouse antibody production (MAP) test, by cell culture, or alternatively by direct detection of the viral agents by polymerase chain reaction (PCR). The description of procedures for sanitation of infected cell lines or tumours is sparse. The present report describes the procedures used for sanitation of three transplantable murine tumour lines, which were transplanted in vivo in a mouse hepatitis virus (MHV)-infected colony of mice at the Department of Experimental Clinical Oncology (DECO). The tumours were frozen and serially transplanted three times in a quarantine colony of syngenic mice. Serological examination of the mice transplanted with tumours as well as their cage mates in the quarantine colony did not detect any antibodies against MHV. After repeated serial transplantation in seronegative animals, tumour material was frozen and thawed tumours were later used for transplantation into the newly established virus-free colony of mice at DECO. PCR-based detection of MHV did not reveal any contamination of the tumour examined by this technique, indicating that this murine tumour apparently did not transmit MHV or that MHV was eliminated from the tissue so fast after the infection that it could not be transmitted by the tumour tissue. It is concluded that MHV infection of mice with transplantable murine tumours does not necessarily cause the tumours to be contaminated.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/blood
- Cell Line, Tumor/virology
- Coronavirus Infections/prevention & control
- Coronavirus Infections/transmission
- Coronavirus Infections/virology
- Crosses, Genetic
- DNA, Viral/chemistry
- DNA, Viral/genetics
- Female
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Animal/transmission
- Hepatitis, Viral, Animal/virology
- Male
- Mice
- Mice, Inbred C3H
- Mice, Inbred DBA
- Murine hepatitis virus/genetics
- Murine hepatitis virus/growth & development
- Neoplasm Transplantation
- Neoplasms, Experimental/virology
- Polymerase Chain Reaction
Collapse
Affiliation(s)
- F Dagnaes-Hansen
- Institute of Medical Microbiology and Immunology, Bartholin Building, University of Aarhus, Denmark.
| | | |
Collapse
|
4
|
Yin F, Jing L, Zhang S, Yu M, Zhang W, Fan G, Dong X, Liu W. [Development and evaluation of an inactivated bivalent vaccine against duck viral hepatitis]. Sheng Wu Gong Cheng Xue Bao 2015; 31:1579-1588. [PMID: 26939441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
The rapid mutation and widely spread of duck hepatitis A virus (DHAV) lead to the vast economic loss of the duck industry. To prepare and evaluate bivalent inactivated vaccine laboratory products of DHAV, 6 strains were screened from 201 DHAV-1 strains and 38 DHAV-3 strains by using serotype epidemiological analysis in most of the duck factory. Vaccine candidate strains were selected by ELD50 and LD50 tests in the 6 strains. Continuously passaged, the 5th passaged duck embryos bodies grinding fluid was selected as vaccine virus seeds. The virus seeds were treated with formaldehyde and water in oil in water (W/O/W) emulsions, making into three batches of two bivalent inactivated vaccine laboratory products. The safety test, antibody neutralization test, challenged protection and cross immune protection experiment suggested that the vaccines possessed good safety, and neutralizing antibodies were detected at 7th day and the challenged protection rate reached 90% to 100% at the 14th and 21st day. Moreover, immune duration of ducklings lasted more than five weeks. However, cross-immunity protection experiments with DHAV-SH and DHAV-FS only had 20%-30%. The two bivalent inactivated vaccine laboratory products of duck viral hepatitis were effective and reliable, providing a new method as well as a new product for DHAV prevention and control.
Collapse
|
5
|
Khawaja G, Buronfosse T, Jamard C, Abdul F, Guerret S, Zoulim F, Luxembourg A, Hannaman D, Evans CF, Hartmann D, Cova L. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins. Virology 2012; 433:192-202. [PMID: 22921316 DOI: 10.1016/j.virol.2012.07.014] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2012] [Revised: 06/01/2012] [Accepted: 07/16/2012] [Indexed: 12/15/2022]
Abstract
This preclinical study investigated the therapeutic efficacy of electroporation (EP)-based delivery of plasmid DNA (pDNA) encoding viral proteins (envelope, core) and IFN-γ in the duck model of chronic hepatitis B virus (DHBV) infection. Importantly, only DNA EP-therapy resulted in a significant decrease in mean viremia titers and in intrahepatic covalently closed circular DNA (cccDNA) levels in chronic DHBV-carrier animals, compared with standard needle pDNA injection (SI). In addition, DNA EP-therapy stimulated in all virus-carriers a humoral response to DHBV preS protein, recognizing a broader range of major antigenic regions, including neutralizing epitopes, compared with SI. DNA EP-therapy led also to significant higher intrahepatic IFN-γ RNA levels in DHBV-carriers compared to other groups, in the absence of adverse effects. We provide the first evidence on DNA EP-therapy benefit in terms of hepadnaviral infection clearance and break of immune tolerance in virus-carriers, supporting its clinical application for chronic hepatitis B.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/immunology
- Chronic Disease
- DNA, Circular/genetics
- DNA, Circular/immunology
- Disease Models, Animal
- Ducks
- Electroporation
- Epitopes
- Hepadnaviridae Infections/immunology
- Hepadnaviridae Infections/prevention & control
- Hepadnaviridae Infections/veterinary
- Hepadnaviridae Infections/virology
- Hepatitis B Vaccines/administration & dosage
- Hepatitis B Vaccines/immunology
- Hepatitis B Virus, Duck/immunology
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Animal/virology
- Immune Tolerance
- Immunity, Humoral
- Interferon-gamma/biosynthesis
- Interferon-gamma/immunology
- Plasmids
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/immunology
- Viral Core Proteins/genetics
- Viral Core Proteins/immunology
- Viral Envelope Proteins/genetics
- Viral Envelope Proteins/immunology
- Viremia/immunology
- Viremia/prevention & control
- Viremia/veterinary
- Viremia/virology
Collapse
|
6
|
Mochizuki S, Sakurai K. Dectin-1 targeting delivery of TNF-α antisense ODNs complexed with β-1,3-glucan protects mice from LPS-induced hepatitis. J Control Release 2011; 151:155-61. [PMID: 21281680 DOI: 10.1016/j.jconrel.2011.01.026] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2010] [Revised: 01/06/2011] [Accepted: 01/24/2011] [Indexed: 01/13/2023]
Abstract
Antisense therapy, the first concept of oligonucleotide therapeutics, was proposed more than two decades ago. However, the lack of suitable delivering carriers continues to be a major obstacle to practical therapy. In this study, we present a novel complex consisting of β-1,3-glucan and antisense oligonucleotide (AS-ODN) as a new candidate of the carriers. We used schizophyllan (SPG) as a β-1,3-glucan and an AS-ODN sequence to suppress tumor necrosis factor alpha (TNF-α), where the AS-ODN has a (dA)(60) tail to induce complex with SPG. When the complexes were applied to peritoneal macrophages, they were incorporated into the cells via dectin-1 (a β-1,3-glucan receptor expressed on antigen presenting cells) and suppressed lipopolysaccharide (LPS)-induced TNF-α secretion. In-vivo, AS-ODN/SPG decreased the secretion of TNF-α in serum and drastically reduced the inflammation of LPS-induced hepatitis. This new complex could overcome the long outstanding problem for antisense therapy because of its complexation ability, non-toxicity and high target specificity.
Collapse
MESH Headings
- Animals
- Cells, Cultured
- Chemical and Drug Induced Liver Injury/metabolism
- Chemical and Drug Induced Liver Injury/prevention & control
- Drug Delivery Systems/methods
- Hepatitis, Viral, Animal/metabolism
- Hepatitis, Viral, Animal/prevention & control
- Lectins, C-Type/administration & dosage
- Lectins, C-Type/physiology
- Lipopolysaccharides/toxicity
- Mice
- Mice, Inbred C57BL
- Oligonucleotides, Antisense/administration & dosage
- Oligonucleotides, Antisense/metabolism
- Protective Agents/administration & dosage
- Protective Agents/pharmacology
- Tumor Necrosis Factor-alpha/antagonists & inhibitors
- Tumor Necrosis Factor-alpha/blood
- beta-Glucans/administration & dosage
- beta-Glucans/chemistry
- beta-Glucans/metabolism
Collapse
Affiliation(s)
- Shinichi Mochizuki
- Department of Chemistry and Biochemistry, The University of Kitakyushu, 1-1 Hibikino, Wakamatsu-ku, Kitakyushu, Fukuoka, Japan
| | | |
Collapse
|
7
|
Jin X, Zhang W, Zhang W, Gu C, Cheng G, Hu X. Identification and molecular analysis of the highly pathogenic duck hepatitis virus type 1 in Hubei province of China. Res Vet Sci 2008; 85:595-8. [PMID: 18486957 DOI: 10.1016/j.rvsc.2008.01.001] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2007] [Revised: 12/24/2007] [Accepted: 01/07/2008] [Indexed: 11/18/2022]
Abstract
Duck hepatitis virus types 1 (DHV-1) JX strain was isolated from infected ducklings with clinical symptoms from Hubei province of China. These isolated strains showed high pathogenicity to both duck embryo and duckling in Duck embryo neutralization assay and animal infection experiment. The complete genome of JX strain was sequenced. Comparative genome analysis with other available strains in GenBank indicated that JX strain shared 94-99% similarity at the nucleotide level and 95-99% at amino acid level with other DHV-1 strains. Sequence results showed that mutations of nucleotide and amino acid were mainly distributed in VP1 genes. Our result implied that the VP1 probably was the major virulent determinant of DHV-1. In addition, 13 DHV-1 strains from different area were analyzed in phylogeny and they can be grouped into four distinct lineages. The new-identified JX strain was grouped into one lineage with A66 and C80 strains, which were also isolated from China.
Collapse
Affiliation(s)
- Xin Jin
- College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, People's Republic of China
| | | | | | | | | | | |
Collapse
|
8
|
Abstract
AIM To study the efficacy of antiviral treatment with PNA for the duck model of HBV (DHBV)-infected ducks. PNA is a 2-amine-9-(2,3-dideoxy-2,3-dihydro-beta-D-arabinofuranosyl)-6-methoxy-9H-purine. METHODS The Sichuan Mallard ducklings in the hepatitis B virus model were treated with PNA, a new antiviral agent. DHBV DNA from the blood serum and liver tissues were measured at 0, 5, and 10 d during the treatment and at 3 d withdrawal by real-time PCR. The duck hepatitis B surface antigen (DHBsAg) in the liver cells was observed by Immunohistochemistry (IHC). Pathological changes in the liver tissues were also observed. Control group I was administered with distilled water and control group II was administered with 3-thiacytidine. Treatment group I was administered with PNA at a dose of 40 mg/kg and treatment group II was administered perorally (po) with PNA at a dose of 80 mg/kg. Treatment group III was administered with PNA at a dose of 20 mg/kg and treatment group IV was intravenously administered with PNA at a dose of 40 mg/kg. Each group contained 15 ducklings. RESULTS PNA can significantly lower the DHBV replication levels in serum and liver. Compared with control group II, there were no significant differences in inhibiting efficacy in treatment groups I and III (P>0.05) and there were significant differences in inhibiting efficacy in treatment groups II and IV (P<0.05). Interestingly, significant differences were observed at 3 d withdrawal. The DHBV replication levels in each group slightly increased at 3 d withdrawal, but rebounded slightly in the PNA treatment groups than in control group II (P<0.05). The DHBV replication levels in the treatment groups were lower than in control group I. The DHBV replication levels in sera had a positive relationship with that in the liver, but the DHBV replication levels in the liver was lower than that in sera. Pathological changes in the treatment groups were obviously improved and the changes were associated with liver viral DNA levels. CONCLUSION The results demonstrate that PNA is a strong inhibitor of DHBV replication in the DHBV-infected duck model.
Collapse
MESH Headings
- Animals
- Antigens, Viral/blood
- Antigens, Viral/metabolism
- Antiviral Agents/administration & dosage
- Antiviral Agents/pharmacology
- DNA, Viral/blood
- DNA, Viral/metabolism
- Disease Models, Animal
- Ducks
- Hepadnaviridae Infections/pathology
- Hepadnaviridae Infections/prevention & control
- Hepadnaviridae Infections/virology
- Hepatitis B Virus, Duck/drug effects
- Hepatitis B Virus, Duck/genetics
- Hepatitis B Virus, Duck/immunology
- Hepatitis, Viral, Animal/pathology
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Animal/virology
- Immunohistochemistry
- Liver/drug effects
- Liver/pathology
- Liver/virology
- Purine Nucleosides/administration & dosage
- Purine Nucleosides/pharmacology
- Virus Replication/drug effects
Collapse
Affiliation(s)
- Zong-Yan Chen
- Avian Disease Research Center, College of Animal Science and Veterinary Medicine, Sichuan Agricultural University, Ya-an 625014, China
| | | | | | | | | | | |
Collapse
|
9
|
Züst R, Cervantes-Barragán L, Kuri T, Blakqori G, Weber F, Ludewig B, Thiel V. Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines. PLoS Pathog 2007; 3:e109. [PMID: 17696607 PMCID: PMC1941747 DOI: 10.1371/journal.ppat.0030109] [Citation(s) in RCA: 182] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2007] [Accepted: 06/12/2007] [Indexed: 01/29/2023] Open
Abstract
Attenuated viral vaccines can be generated by targeting essential pathogenicity factors. We report here the rational design of an attenuated recombinant coronavirus vaccine based on a deletion in the coding sequence of the non-structural protein 1 (nsp1). In cell culture, nsp1 of mouse hepatitis virus (MHV), like its SARS-coronavirus homolog, strongly reduced cellular gene expression. The effect of nsp1 on MHV replication in vitro and in vivo was analyzed using a recombinant MHV encoding a deletion in the nsp1-coding sequence. The recombinant MHV nsp1 mutant grew normally in tissue culture, but was severely attenuated in vivo. Replication and spread of the nsp1 mutant virus was restored almost to wild-type levels in type I interferon (IFN) receptor-deficient mice, indicating that nsp1 interferes efficiently with the type I IFN system. Importantly, replication of nsp1 mutant virus in professional antigen-presenting cells such as conventional dendritic cells and macrophages, and induction of type I IFN in plasmacytoid dendritic cells, was not impaired. Furthermore, even low doses of nsp1 mutant MHV elicited potent cytotoxic T cell responses and protected mice against homologous and heterologous virus challenge. Taken together, the presented attenuation strategy provides a paradigm for the development of highly efficient coronavirus vaccines. Prevention of viral diseases by vaccination aims for controlled induction of protective immune responses against viral pathogens. Live viral vaccines consist of attenuated, replication-competent viruses that are believed to be superior in the induction of broad immune responses, including cell-mediated immunity. The recent proceedings in the area of virus reverse genetics allows for the rational design of recombinant vaccines by targeting, i.e., inactivating, viral pathogenicity factors. For coronaviruses, a major pathogenicity factor has now been identified. The effect of coronavirus non-structural protein 1 on pathogenicity has been analyzed in a murine model of coronavirus infection. By deleting a part of this protein, a recombinant virus has been generated that is greatly attenuated in vivo, while retaining immunogenicity. In particular, the mutant virus retained the ability to replicate in professional antigen-presenting cells and fulfilled an important requirement of a promising vaccine candidate: the induction of a protective long-lasting, antigen-specific cellular immune response. This study has implications for the rational design of live attenuated coronavirus vaccines aimed at preventing coronavirus-induced diseases of veterinary and medical importance, including the potentially lethal severe acute respiratory syndrome.
Collapse
MESH Headings
- Animals
- Base Sequence
- Cells, Cultured
- DNA, Viral
- Disease Models, Animal
- Drug Design
- Gene Deletion
- Gene Silencing
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Humans
- Interferon Type I/deficiency
- Interferon Type I/genetics
- Liver/metabolism
- Liver/pathology
- Liver/virology
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Molecular Sequence Data
- Murine hepatitis virus/immunology
- Murine hepatitis virus/pathogenicity
- Recombinant Proteins/immunology
- Vaccines, Attenuated/immunology
- Viral Nonstructural Proteins/genetics
- Viral Nonstructural Proteins/immunology
- Viral Nonstructural Proteins/metabolism
- Viral Vaccines/immunology
- Virulence Factors/immunology
- Virus Replication
Collapse
Affiliation(s)
- Roland Züst
- Research Department, Kantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Luisa Cervantes-Barragán
- Research Department, Kantonal Hospital St. Gallen, St. Gallen, Switzerland
- Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, México
| | - Thomas Kuri
- Department of Virology, University of Freiburg, Freiburg, Germany
| | - Gjon Blakqori
- Department of Virology, University of Freiburg, Freiburg, Germany
| | - Friedemann Weber
- Department of Virology, University of Freiburg, Freiburg, Germany
| | - Burkhard Ludewig
- Research Department, Kantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Volker Thiel
- Research Department, Kantonal Hospital St. Gallen, St. Gallen, Switzerland
- * To whom correspondence should be addressed. E-mail:
| |
Collapse
|
10
|
Walsh KB, Edwards RA, Romero KM, Kotlajich MV, Stohlman SA, Lane TE. Expression of CXC chemokine ligand 10 from the mouse hepatitis virus genome results in protection from viral-induced neurological and liver disease. J Immunol 2007; 179:1155-65. [PMID: 17617609 DOI: 10.4049/jimmunol.179.2.1155] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Using the recombinant murine coronavirus mouse hepatitis virus (MHV) expressing the T cell-chemoattractant CXCL10 (MHV-CXCL10), we demonstrate a potent antiviral role for CXCL10 in host defense. Instillation of MHV-CXCL10 into the CNS of CXCL10-deficient (CXCL10(-/-)) mice resulted in viral infection and replication in both brain and liver. Expression of virally encoded CXCL10 within the brain protected mice from death and correlated with increased infiltration of T lymphocytes, enhanced IFN-gamma secretion, and accelerated viral clearance when compared with mice infected with an isogenic control virus, MHV. Similarly, viral clearance from the livers of MHV-CXCL10-infected mice was accelerated in comparison to MHV-infected mice, yet was independent of enhanced infiltration of T lymphocytes and NK cells. Moreover, CXCL10(-/-) mice infected with MHV-CXCL10 were protected from severe hepatitis as evidenced by reduced pathology and serum alanine aminotransferase levels compared with MHV-infected mice. CXCL10-mediated protection within the liver was not dependent on CXC-chemokine receptor 2 (CXCR2) signaling as anti-CXCR2 treatment of MHV-CXCL10-infected mice did not modulate viral clearance or liver pathology. In contrast, treatment of MHV-CXCL10-infected CXCL10(-/-) mice with anti-CXCL10 Ab resulted in increased clinical disease correlating with enhanced viral recovery from the brain and liver as well as increased serum alanine aminotransferase levels. These studies highlight that CXCL10 expression promotes protection from coronavirus-induced neurological and liver disease.
Collapse
MESH Headings
- Alanine Transaminase/blood
- Animals
- Brain/pathology
- Brain/virology
- Central Nervous System Diseases/immunology
- Central Nervous System Diseases/prevention & control
- Central Nervous System Diseases/virology
- Chemokine CXCL10
- Chemokines, CXC/genetics
- Chemokines, CXC/immunology
- Chemokines, CXC/metabolism
- Coronavirus Infections/immunology
- Coronavirus Infections/prevention & control
- Coronavirus Infections/virology
- Enzyme-Linked Immunosorbent Assay
- Fluorescent Antibody Technique
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Animal/virology
- Interferon-gamma/metabolism
- Killer Cells, Natural/immunology
- Liver/pathology
- Liver/virology
- Mice
- Murine hepatitis virus/genetics
- Murine hepatitis virus/pathogenicity
- Receptors, Interleukin-8B/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Spinal Cord/pathology
- Spinal Cord/virology
- T-Lymphocytes/immunology
Collapse
Affiliation(s)
- Kevin B Walsh
- Department of Molecular Biology & Biochemistry, University of California, Irvine, CA 92697, USA
| | | | | | | | | | | |
Collapse
|
11
|
Alvarado IR, Villegas P, El-Attrache J, Jensen E, Rosales G, Perozo F, Purvis LB. Genetic characterization, pathogenicity, and protection studies with an avian adenovirus isolate associated with inclusion body hepatitis. Avian Dis 2007; 51:27-32. [PMID: 17461263 DOI: 10.1637/0005-2086(2007)051[0027:gcpaps]2.0.co;2] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
An avian adenovirus (AAV) was isolated from liver samples of two 2-wk-old broiler-breeder flocks obtained from grandparents vaccinated at 10 and 17 wks of age with an autogenous inactivated vaccine containing the European AAV 8 (8565 strain) and 11 (1047 strain) serotypes (AAV8/11 vaccine). Affected broiler-breeders exhibited clinical signs and macroscopic and microscopic lesions associated with inclusion body hepatitis (IBH). The isolated adenovirus, identified as Stanford, was molecularly characterized as European serotype 9. The pathogenicity of the Stanford strain was confirmed after inoculation of specific-pathogen-free (SPF) chickens at 1-7 days of age, causing 100% and 20% mortality, respectively. The level of protection against IBH was evaluated in two broiler-breeder progenies from AAV 8/11-vaccinated grandparent flocks and a commercial broiler flock by challenge at 1 or 7 days of age with the AAV 8 and 11 serotypes and/or the Stanford strain. The broiler-breeder progenies and the commercial broiler flock exhibited protection against IBH after challenge. No significant differences in mean body weights were observed at 3 wk of age in any of the evaluated groups. We conclude that broiler-breeder progenies from 30- to 50-wk-old grandparents vaccinated with the AAV 8/11 vaccine were adequately protected against challenge with the AAV 8 and 11 serotypes and the Stanford strain.
Collapse
Affiliation(s)
- I R Alvarado
- Department of Population Health, University of Georgia, Athens, GA 30602, USA
| | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Hepatitis B and C infections are two of the most prevalent viral diseases in the world. Existing therapies against chronic viral hepatitis are far from satisfactory due to low response rates, undesirable side effects and selection of resistant viral strains. Therefore, new therapeutic approaches are urgently needed. This review, after briefly summarising the in vitro and in vivo systems for the study of both diseases and the genetic vehicles commonly used for liver gene transfer, examines the existing status of gene therapy-based antiviral strategies that have been employed to prevent, eliminate or reduce viral infection. In particular, the authors focus on the results obtained in clinical trials and experimental clinically relevant animal models.
Collapse
MESH Headings
- Animals
- Disease Models, Animal
- Genetic Therapy/methods
- Genetic Therapy/trends
- Hepatitis B, Chronic/genetics
- Hepatitis B, Chronic/prevention & control
- Hepatitis C, Chronic/genetics
- Hepatitis C, Chronic/prevention & control
- Hepatitis, Viral, Animal/genetics
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Human/genetics
- Hepatitis, Viral, Human/prevention & control
- Humans
Collapse
Affiliation(s)
- Gloria Gonzalez-Aseguinolaza
- University of Navarra, Division of Gene Therapy and Hepatology, Center for Applied Medical Research (CIMA), 31008 Pamplona, Spain.
| | | | | | | | | | | |
Collapse
|
13
|
Mahabir E, Bulian D, Needham J, Mayer A, Mateusen B, Van Soom A, Nauwynck H, Schmidt J. Transmission of mouse minute virus (MMV) but not mouse hepatitis virus (MHV) following embryo transfer with experimentally exposed in vivo-derived embryos. Biol Reprod 2006; 76:189-97. [PMID: 17021342 PMCID: PMC7109837 DOI: 10.1095/biolreprod.106.056135] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
The present study investigated the presence and location of fluorescent microspheres having the size of mouse hepatitis virus (MHV) and of mouse minute virus (MMV) in the zona pellucida (ZP) of in vivo-produced murine embryos, the transmission of these viruses by embryos during embryo transfer, and the time of seroconversion of recipients and pups. To this end, fertilized oocytes and morulae were exposed to different concentrations of MMVp for 16 h, while 2-cell embryos and blastocysts were coincubated for 1 h. In addition, morulae were exposed to MHV-A59 for 16 h. One group of embryos was washed, and the remaining embryos remained unwashed before embryo transfer. Serological analyses were performed by means of ELISA to detect antibodies to MHV or MMV in recipients and in progeny on Days 14, 21, 28, 42, and 63 and on Days 42, 63, 84, 112, 133, and 154, respectively, after embryo transfer. Coincubation with a minimum of 105/ml of fluorescent microspheres showed that particles with a diameter of 20 nm but not 100 nm crossed the ZP of murine blastocysts. Washing generally led to a 10-fold to 100-fold reduction of MMVp. Washed MMV-exposed but not MHV-exposed embryos led to the production of antibodies independent of embryonic stage and time of virus exposure. Recipients receiving embryos exposed to a minimum of 107 mean tissue culture infective dose (TCID50)/ml of MHV-A59 and 102 TCID50/ml of MMVp seroconverted by Day 42 after embryo transfer. The results indicate that MMV but not MHV can be transmitted to recipients even after washing embryos 10 times before embryo transfer.
Collapse
Affiliation(s)
- Esther Mahabir
- Department of Comparative Medicine, GSF-National Research Center for Environment and Health, D-85764 Neuherberg, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Stegniĭ MI. [Development of the methods of cryopreservation and lyophilization of vaccine against duckling hepatitis virus from "K-IP" strain]. Mikrobiol Z 2006; 68:78-84. [PMID: 17100332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
A method is developed of kryopreservation of a liquid virus vaccine against duck hepatitis virus in liquid nitrogen at -196 degrees C or in its pairs (-168 to - 175 degrees C) with the subsequent fast defreezing on water bath at 40 degrees C within 2 minutes allowing to keep to initial property of a vaccine within 2 years (the period of supervision) and the rules of vaccine lyophilization with application of three-component protective environment, with 6% of peptone, 4.8% of sorbite, 1% of gelatin with sublimation chamber temperature no less than -40 degrees C in the first 4 h of lyophilization ensuring prolongation of storage term of the a liquid vaccine from 6 months in conditions of hypothermic storage (4-8 degrees C) to one year in the dried up condition.
Collapse
|
15
|
Cham BE, Vickery K, Tohidi-Esfahani R, Cossart Y. Delipidation of a hepadnavirus: Viral inactivation and vaccine development. J Virol Methods 2006; 137:160-3. [PMID: 16808980 DOI: 10.1016/j.jviromet.2006.05.027] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2005] [Revised: 05/21/2006] [Accepted: 05/25/2006] [Indexed: 11/22/2022]
Abstract
Many viruses including HIV, hepatitis C and hepatitis B, have an outer lipid envelope which maintains inserted viral peptides in the "correct" functional conformation and orientation. Disruption of the lipid envelope by most solvents destroys infectivity and often results in a loss of antigenicity. This communication outlines a novel approach to viral inactivation by specific solvent delipidation which modifies the whole virion rendering it non-infective, but antigenic. Duck hepatitis B virus (DHBV) was delipidated using a diisopropylether (DIPE) and butanol mixture and residual infectivity tested by inoculation into day-old ducks. Delipidation completely inactivated the DHBV (p < 0.001). Delipidated DHBV was then used to vaccinate ducks. Three doses of delipidated DHBV induced anti-DHBs antibody production and prevented high dose challenge infection in five out of six ducks. In comparison, five of six ducks vaccinated with undelipidated DHBV and four of four ducks vaccinated with glutaraldehyde inactivated DHBV were unprotected (p < 0.05). Although this solvent system completely inactivated DHBV, viral antigens were retained in an appropriate form to induce immunity. Delipidation of enveloped viruses with specific organic solvents has potential as the basis for development of vaccines.
Collapse
Affiliation(s)
- B E Cham
- Department of Medicine, University of Queensland, Royal Brisbane Hospital, Qld 4029, Australia.
| | | | | | | |
Collapse
|
16
|
Miller DS, Halpern M, Kotlarski I, Jilbert AR. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection. Virology 2006; 348:297-308. [PMID: 16469347 DOI: 10.1016/j.virol.2005.12.032] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2005] [Revised: 10/12/2005] [Accepted: 12/22/2005] [Indexed: 01/12/2023]
Abstract
As a first step in developing immuno-therapeutic vaccines for patients with chronic hepatitis B virus infection, we examined the ability of a whole-cell vaccine, expressing the duck hepatitis B virus (DHBV) core antigen (DHBcAg), to target infected cells leading to the resolution of de novo DHBV infections. Three separate experiments were performed. In each experiment, ducks were vaccinated at 7 and 14 days of age with primary duck embryonic fibroblasts (PDEF) that had been transfected 48 h earlier with plasmid DNA expressing DHBcAg with and without the addition of anti-DHBcAg (anti-DHBc) antibodies. Control ducks were injected with either 0.7% NaCl or non-transfected PDEF. The ducks were then challenged at 18 days of age by intravenous inoculation with DHBV (5 x 10(8) viral genome equivalents). Liver biopsies obtained on day 4 post-challenge demonstrated that vaccination did not prevent infection of the liver as similar numbers of infected hepatocytes were detected in all vaccinated and control ducks. However, analysis of liver tissue obtained 9 or more days post-challenge revealed that 9 out of 11 of the PDEF-DHBcAg vaccinated ducks and 8 out of 11 ducks vaccinated with PDEF-DHBcAg plus anti-DHBc antibodies had rapidly resolved the DHBV infection with clearance of infected cells. In contrast, 10 out of 11 of the control unvaccinated ducks developed chronic DHBV infection. In conclusion, vaccination of ducks with a whole-cell PDEF vaccine expressing DHBcAg elicited immune responses that induced a rapid resolution of DHBV infection. The results establish that chronic infection can be prevented via the vaccine-mediated induction of a core-antigen-specific immune response.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/biosynthesis
- Antigens, Viral/genetics
- Base Sequence
- DNA, Viral/genetics
- DNA, Viral/isolation & purification
- Ducks/immunology
- Ducks/virology
- Fibroblasts/immunology
- Fibroblasts/virology
- Hepadnaviridae Infections/immunology
- Hepadnaviridae Infections/prevention & control
- Hepadnaviridae Infections/veterinary
- Hepadnaviridae Infections/virology
- Hepatitis B Virus, Duck/genetics
- Hepatitis B Virus, Duck/immunology
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Animal/virology
- Humans
- Plasmids/genetics
- Poultry Diseases/immunology
- Poultry Diseases/prevention & control
- Poultry Diseases/virology
- Transfection
- Viral Core Proteins/genetics
- Viral Core Proteins/immunology
- Viral Hepatitis Vaccines/genetics
- Viral Hepatitis Vaccines/immunology
Collapse
Affiliation(s)
- Darren S Miller
- School of Molecular and Biomedical Science, The University of Adelaide, Australia.
| | | | | | | |
Collapse
|
17
|
Abstract
AIM: To detect the effects of DNA vaccines in combination with duck IFN-γ gene on the protection of ducks against duck hepatitis B virus (DHBV) infection.
METHODS: DuIFN-γ cDNA was cloned and expressed in COS-7 cells, and the antiviral activity of DuIFN-γ was detected and neutralized by specific antibodies. Ducks were vaccinated with DHBpreS/S DNA alone or co-immunized with plasmid expressing DuIFN-γ. DuIFN-γ mRNA in peripheral blood mononuclear cells (PBMCs) from immunized ducks was detected by semi-quantitative competitive RT-PCR. Anti-DHBpreS was titrated by enzyme-linked immunosorbent assay (ELISA). DHBV DNA in sera and liver was detected by Southern blot hybridization, after ducks were challenged with high doses of DHBV.
RESULTS: DuIFN-γ expressed by COS-7 was able to protect duck fibroblasts against vesicular stomatitis virus (VSV) infection in a dose-dependent fashion, and anti-DuIFN-γ antibodies neutralized the antiviral effects. DuIFN-γ in the supernatant also inhibited the release of DHBV DNA from LMH-D2 cells. When ducks were co-immunized with DNA vaccine expressing DHBpreS/S and DuIFN-γ gene as an adjuvant, the level of DuIFN-γ mRNA in PBMCs was higher than that in ducks vaccinated with DHBpreS/S DNA alone. However, the titer of anti-DHBpreS elicited by DHBpreS/S DNA alone was higher than that co-immunized with DuIFN-γ gene and DHBpreS/S DNA. After being challenged with DHBV at high doses, the load of DHBV in sera dropped faster, and the amount of total DNA and cccDNA in the liver decreased more significantly in the group of ducks co-immunized with DuIFN-γ gene and DHBpreS/S DNA than in other groups.
CONCLUSION: DHBV preS/S DNA vaccine can protect ducks against DHBV infection, DuIFN-γ gene as an immune adjuvant enhances its efficacy.
Collapse
Affiliation(s)
- Jian-Er Long
- Department of Molecular Virology, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | | | | | | | | |
Collapse
|
18
|
Lu M, Isogawa M, Xu Y, Hilken G. Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J Virol 2005; 79:6368-76. [PMID: 15858020 PMCID: PMC1091665 DOI: 10.1128/jvi.79.10.6368-6376.2005] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
A number of options are available to modify and improve DNA vaccines. An interesting approach to improve DNA vaccines is to fuse bioactive domains, like cytotoxic-T-lymphocyte-associated protein 4 (CTLA-4), to an antigen. Such fusion antigens are expressed in vivo and directed to immune cells by the specific bioactive domain and therefore possess great potential to induce and modulate antigen-specific immune responses. In the present study, we tested this new approach for immunomodulation against hepadnavirus infection in the woodchuck model. Plasmids expressing the nucleocapsid protein (WHcAg) and e antigen (WHeAg) of woodchuck hepatitis virus (WHV) alone or in fusion to the extracellular domain of woodchuck CTLA-4 and CD28 were constructed. Immunizations of mice with plasmids expressing WHcAg or WHeAg led to a specific immunoglobulin G2a (IgG2a)-dominant antibody response. In contrast, fusions of WHcAg to CTLA-4 and CD28 induced a specific antibody response with comparable levels of IgG1 and IgG2a. Furthermore, the specific IgG1 response to WHcAg/WHeAg developed immediately after a single immunization with the CTLA-4-WHcAg fusion. Woodchucks were immunized with plasmids expressing WHeAg or the CTLA-4-WHcAg fusion and subsequently challenged with WHV. CTLA-4-WHcAg showed an improved efficacy in induction of protective immune responses to WHV. In particular, the anti-WHsAg antibody response developed earlier after challenge in woodchucks that received immunizations with CTLA-4-WHcAg, consistent with the hypothesis that anti-WHs response is dependent on a Th cell response to WHcAg. In conclusion, the use of fusion genes represents a generally applicable strategy to improve DNA vaccination.
Collapse
MESH Headings
- Animals
- Antibody Specificity
- Antigens, CD
- Antigens, Differentiation/immunology
- CD28 Antigens/immunology
- CTLA-4 Antigen
- Drug Evaluation, Preclinical
- Hepatitis B/blood
- Hepatitis B/immunology
- Hepatitis B/prevention & control
- Hepatitis B Antibodies/blood
- Hepatitis B Vaccines/administration & dosage
- Hepatitis B Vaccines/immunology
- Hepatitis B Virus, Woodchuck/immunology
- Hepatitis, Viral, Animal/blood
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Immunoglobulin G/blood
- Injections, Intramuscular
- Marmota
- Mice
- Mice, Inbred BALB C
- Nucleocapsid/immunology
- Nucleocapsid Proteins
- Plasmids/metabolism
- Vaccination
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/immunology
Collapse
Affiliation(s)
- Mengji Lu
- Institut für Virologie, Universitätsklinikum Essen, Hufelandstrasse 55, Essen D-45122, Germany.
| | | | | | | |
Collapse
|
19
|
Abstract
Severe acute respiratory syndrome (SARS) caused by a newly identified coronavirus (SARS-CoV) remains a threat to cause epidemics as evidenced by recent sporadic cases in China. In this communication, we evaluated the efficacy and safety of two SARS vaccine candidates based on the recombinant modified vaccinia Ankara (MVA) expressing SARS-CoV spike or nucleocapsid proteins in ferrets. No clinical signs were observed in all the ferrets challenged with SARS-CoV. On the other hand, vaccination did not prevent SARS-CoV infection in ferrets. In contrast, immunized ferrets (particularly those immunized with rMVA-spike) exhibited significantly stronger inflammatory responses and focal necrosis in liver tissue after SARS-CoV challenge than control animals. Thus, our data suggest that enhanced hepatitis is linked to vaccination with rMVA expressing SARS-CoV antigens.
Collapse
MESH Headings
- Animals
- Antigens, Viral/genetics
- Base Sequence
- Coronavirus Nucleocapsid Proteins
- DNA, Viral/genetics
- Ferrets
- Hepatitis, Viral, Animal/pathology
- Hepatitis, Viral, Animal/prevention & control
- Male
- Membrane Glycoproteins/genetics
- Membrane Glycoproteins/immunology
- Nucleocapsid Proteins/genetics
- Nucleocapsid Proteins/immunology
- RNA, Viral/analysis
- RNA, Viral/genetics
- Severe acute respiratory syndrome-related coronavirus/genetics
- Severe acute respiratory syndrome-related coronavirus/immunology
- Severe acute respiratory syndrome-related coronavirus/isolation & purification
- Severe Acute Respiratory Syndrome/pathology
- Severe Acute Respiratory Syndrome/prevention & control
- Spike Glycoprotein, Coronavirus
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/pharmacology
- Viral Envelope Proteins/genetics
- Viral Envelope Proteins/immunology
- Viral Vaccines/genetics
- Viral Vaccines/pharmacology
Collapse
Affiliation(s)
- Markus Czub
- National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2
- Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada R3T 2N2
| | - Hana Weingartl
- National Centre for Foreign Animal Diseases, Canadian Science Centre for Human and Animal Health. 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2
- Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada R3T 2N2
| | - Stefanie Czub
- Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada R3T 2N2
| | - Runtao He
- National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2
- Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada R3T 2N2
| | - Jingxin Cao
- National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health, 1015 Arlington Street, Winnipeg, Manitoba, Canada R3E 3R2
- Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada R3T 2N2
- Corresponding author.
| |
Collapse
|
20
|
Abstract
Inclusion-body hepatitis hydropericardium syndrome (IBH-HPS) is an important, recently emerged, disease of poultry, particularly of 3- to 6-week-old broiler chicks, characterized by its sudden onset, with high mortality ranging from 20% to 70%, typical hydropericardium and enlarged mottled and friable livers, with intranuclear inclusion bodies in the hepatocytes. The causative agent is a non-enveloped icosahedral fowl adenovirus (FAV) serotype 4, belonging to the Adenovirus genus of the family Adenoviridae, which can be propagated or cultivated in chicken embryo liver and kidney primary cell cultures. The transmission of disease occurs vertically and laterally by the oral-faecal route. The liver of infected birds shows necrotic foci and basophilic intranuclear inclusion bodies in the hepatocytes. The disease can be diagnosed from its gross and histopathological changes in the liver and by various serological tests, such as agar gel immunodiffusion, counterimmunoelectrophoresis, indirect haemagglutination, the fluorescent antibody technique, enzyme-linked immunosorbent assay and the polymerase chain reaction. The disease has been brought under control by the use of formalin-inactivated vaccines, prepared from infected liver homogenate, and of inactivated cell culture vaccines. The vaccines are effective in the face of natural outbreaks or experimental challenge and significantly reduce the mortality.
Collapse
Affiliation(s)
- V Balamurugan
- Division of Avian Diseases, Indian Veterinary Research Institute, Izatnagar, Bareilly, UP 243 122, India
| | | |
Collapse
|
21
|
Abstract
Allitridin (diallyl trisulfide), a main effective compound of Allium sativum (garlic), was previously shown to inhibit the expression of immediate-early antigens and viral proliferation of human cytomegalovirus (HCMV) in vitro. Here we have examined the prophylactic and therapeutic efficacy of allitridin in a non-lethal murine cytomegalovirus (MCMV) hepatitis in methylprednisolone-immunosuppressed BALB/c mice. Allitridin was administered at 25mg/kg per day (equal to the mean human dose) and 75 mg/kg per day in two regimens: prophylaxis plus therapy beginning at 2 days before infection and lasting for 18 days, and therapy lasting for 14 days initiated at 2 days after infection. Ganciclovir (GCV)-treated, infected, and non-infected mice served as controls. MCMV DNA load in the liver, plasma alanine aminotransferase (ALT) level and Knodell's histological activity index (HAI) score of liver section were evaluated. We found that MCMV DNA load was significantly decreased in all allitridin- and GCV-treated mice, compared with infected controls. Concomitantly, histopathological lesions in the liver and plasma ALT levels were reduced. Statistically, no significant differences were detected between the combined allitridin prophylaxis plus therapeutic and therapeutic groups regardless of dose and the GCV groups. Our results demonstrate the therapeutic efficacy of allitridin in mouse models with MCMV hepatitis.
Collapse
Affiliation(s)
- Zhi-Feng Liu
- Laboratory of Pediatric Clinical Virology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, PR China
| | | | | | | | | |
Collapse
|
22
|
Toro H, González C, Cerda L, Morales MA, Dooner P, Salamero M. Prevention of inclusion body hepatitis/hydropericardium syndrome in progeny chickens by vaccination of breeders with fowl adenovirus and chicken anemia virus. Avian Dis 2003; 46:547-54. [PMID: 12243517 DOI: 10.1637/0005-2086(2002)046[0547:poibhh]2.0.co;2] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The hypothesis that an effective protection of progeny chickens against inclusion body hepatitis/hydropericardium syndrome (IBH/HP) can be achieved by dual vaccination of breeders with fowl adenovirus (FAV) serotype 4 and chicken anemia virus (CAV) was tested. Thus, 17-wk-old brown leghorn pullet groups were vaccinated by different schemes including single FAV (inactivated), single CAV (attenuated), FAV and CAV dually, or were not vaccinated (controls). Subsequent progenies of these breeders were challenged with the virulent strains FAV-341 and CAV-10343 following three strategies: 1) FAV-341 intramuscularly (i.m.) at day 10 of age (only FAV-vaccinated and control progenies); 2) FAV + CAV i.m. simultaneously at day 10 of age (all progenies); 3) CAV i.m. at day 1 and FAV orally at day 10 of age (all progenies). The induction of IBH/HP in these progenies was evaluated throughout a 10-day period. Both breeder groups vaccinated against FAV and those vaccinated against CAV increased virus neutralizing specific antibodies. Challenge strategy 1 showed 26.6% mortality in control progeny chickens and 13.3% in the progeny of FAV-vaccinated breeders. Presence of lesions in the liver of these groups showed no significant differences (P > 0.05), suggesting a discreet protective effect of the vaccine. Challenge strategy 2 showed 29.4% mortality in controls and 94% of chickens showed hepatic inclusion bodies (HIB). Single CAV vaccination of breeders did not demonstrate a beneficial effect, with both mortality and liver lesions resembling the nonvaccinated controls. FAV vaccination of breeders significantly reduced both mortality (7.4%) and liver lesions (26% HIB) (P < 0.05), providing protection against this challenge strategy. Dual vaccination of breeders with FAV and CAV proved to be necessary to achieve maximum protection of the progeny (no mortality and 7% HIB). Challenge strategy 3 produced no mortality but consistent liver damage in controls (96% HIB). In this case, both CAV and FAV + CAV-vaccinated breeders showed best protection results in terms of liver histopathology (8% and 0% HIB, respectively). FAV vaccination alone produced 24% HIB, similar to challenge strategy 2, demonstrating a lower protective effect.
Collapse
MESH Headings
- Adenoviridae Infections/prevention & control
- Adenoviridae Infections/veterinary
- Animals
- Antibodies, Viral/blood
- Aviadenovirus/immunology
- Chicken anemia virus/immunology
- Chickens
- Circoviridae Infections/prevention & control
- Circoviridae Infections/veterinary
- Female
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Hepatitis, Viral, Animal/virology
- Inclusion Bodies, Viral/immunology
- Inclusion Bodies, Viral/virology
- Infectious Disease Transmission, Vertical/veterinary
- Liver/pathology
- Liver/virology
- Pericardial Effusion/immunology
- Pericardial Effusion/prevention & control
- Pericardial Effusion/veterinary
- Pericardium/pathology
- Pericardium/virology
- Poultry Diseases/immunology
- Poultry Diseases/prevention & control
- Poultry Diseases/virology
- Syndrome
- Vaccination/veterinary
- Viral Vaccines
Collapse
Affiliation(s)
- H Toro
- Faculty of Veterinary Sciences, University Chile, Santiago
| | | | | | | | | | | |
Collapse
|
23
|
Abstract
Increasing lines of evidence suggest that DNA vaccine is of interest to fight chronic hepatitis B virus (HBV) infection. We used the Pekin duck infected by duck HBV (DHBV), closely related to the human virus, which is an attractive model allowing study of protective and therapeutic effectiveness of DNA vaccines against hepatitis B. Immunisation with a plasmid encoding the DHBV large (L) envelope protein induced a strong, specific, highly neutralising and long-lasting anti-preS humoral response in uninfected ducks. Importantly, maternal antibodies elicited by such DNA immunisation were vertically transmitted and protected progeny against viral challenge. Therapeutic immunisation of chronic DHBV-carrier ducks with this plasmid DNA led to the dramatic and sustained decrease in viral replication and even to clearance of intrahepatic viral covalently close circular DNA (cccDNA) pool in some animals. Our recent combination therapy data showed even a more pronounced antiviral effect of DNA vaccine to DHBV envelope protein when associated with antiviral drug (lamivudine) treatment. Therefore, DNA-based vaccine appears as a promising new approach for prophylaxis and therapy of hepatitis B.
Collapse
MESH Headings
- Animals
- Chronic Disease
- DNA, Viral/blood
- DNA, Viral/genetics
- Disease Models, Animal
- Ducks
- Hepadnaviridae Infections/diet therapy
- Hepadnaviridae Infections/immunology
- Hepadnaviridae Infections/prevention & control
- Hepatitis B Antibodies/blood
- Hepatitis B Vaccines/administration & dosage
- Hepatitis B Vaccines/immunology
- Hepatitis B Vaccines/therapeutic use
- Hepatitis B Virus, Duck/genetics
- Hepatitis B Virus, Duck/immunology
- Hepatitis, Viral, Animal/drug therapy
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/immunology
- Vaccines, DNA/therapeutic use
Collapse
|
24
|
Smith GD, Solenberg PJ, Koenig MC, Brune KA, Fox N. Use of TaqMan reverse transcriptase-polymerase chain reaction analysis and serologic testing to eliminate an enzootic infection of mouse hepatitis virus. Comp Med 2002; 52:456-60. [PMID: 12405640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Abstract
Elimination of an enzootic infection of mouse hepatitis virus (MHV) from a large population of genetically engineered mice was accomplished by selecting seropositive, non-infective breeders for a newly restored MHV-free breeding colony. An ELISA was used to test for the presence of MHV-specific antibody, and TaqMan reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was used to detect MHV in the feces. After 10 weeks of intentional exposure, approximately 30% of mice with MHV antibodies continued to shed MHV in the feces. A natural transmission study was conducted to validate that positive fecal RT-PCR results indicated presence of infective virus. Sentinel results from the re-instituted breeding colony indicated that MHV was successfully eliminated by use of RT-PCR analysis for selection of non-infective mice.
Collapse
Affiliation(s)
- Gerald D Smith
- Eli Lilly and Company, Veterinary Resources, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
| | | | | | | | | |
Collapse
|
25
|
Macy JD, Cameron GA, Ellis SL, Hill EA, Compton SR. Assessment of static isolator cages with automatic watering when used with conventional husbandry techniques as a factor in the transmission of mouse hepatitis virus. Contemp Top Lab Anim Sci 2002; 41:30-5. [PMID: 12109894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
This study evaluated protection against mouse hepatitis virus (MHV) afforded by static filter-top caging when automatic watering was used with conventional husbandry techniques as a labor-saving option. We fitted one side of a double-sided 72-cage rack with valves external to each cage; cages on the other side were fitted with shielded internal valves. More than 50% of the mice were breeding mice, and 30% were genetically altered. One cage of mice on each shelf on both sides of the rack was infected with MHV-A59. Each row of cages also contained one standard cage (no filter top) of uninoculated mice at various distances from the infected cage. At 2, 4, and 6 weeks after infection of the mice in the test cages, uninoculated mice in 22 cages were tested by serology, and at 8 weeks the uninoculated mice in 54 cages were tested by serology and those in 24 cages were tested by polymerase chain reaction (PCR) amplification of fecal samples to assess transmission of infection. At 8 weeks post-infection, mice in one uninoculated cage (which had a filter top and an internal valve and was adjacent to a cage of inoculated mice) was seropositive. Examination of feces by PCR revealed MHV shedding in mice in nine uninoculated cages (three lacking filter tops but with internal valve cages; two with filter tops and internal valve cages and adjacent to non-filter top cages; two non-filter-top cages with external valves; and two filter-top cages with external valves, of which one was adjacent to a non-filter-top cage). Routine husbandry using either automatic water valve system prevented (with one exception) transmission among filter-top cages for at least 6 weeks. The 10 cages where transmission occurred were non-filter-top cages (n = 5) and filter-top cages adjacent to non-filter top, infected, or sentinel cages (n = 5). These results suggest that the use of filter top-caging with automatic watering may limit MHV transmission for 6 weeks, during which immunocompetent mice would be expected to clear the virus. Our findings also suggest that long-term use of automatic watering in static filter-top cages handled using conventional husbandry techniques may not prevent transmission in the vicinity of high virus concentrations or open caging.
Collapse
Affiliation(s)
- James D Macy
- Yale University, Section of Comparative Medicine, PO Box 208016, New Haven, Connecticut 06520-8016, USA
| | | | | | | | | |
Collapse
|
26
|
Liang Z, Lan Y, Li Y, Cai D, Ren H. [Construction of eukaryotic expression plasmids inserting HBsAg gene and DNA immunization responses to HBsAg in mice]. Zhonghua Gan Zang Bing Za Zhi 2002; 10:106-8. [PMID: 11983125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/24/2023]
Abstract
OBJECTIVE To study the HBsAg transient expression in HepG2 or COS-7 cells with eukaryotic expression plasmids inserting HBsAg gene (pCI-S and pcDNA3.1-S) and the efficacy of naked DNA immunization in mice. METHODS Firstly, the recombinant plasmids of pCI-S and pcDNA3.1-S were constructed by the cloning technique and the accuracy of these constructs was confirmed by restriction enzyme digestion and DNA sequencing. Secondly, plasmids of pCI-S and pcDNA3.1-S were transferred into HepG2 and COS-7 cells, respectively by means of cationic liposome. HBsAg transient expression was assayed by ELISA in cell culture supernatants and cell lysates. Thirdly, plasmids were injected into quadriceps muscles of BALB/C mice and serum samples were obtained from individual immunized or control mice 4 weeks after injection and boost injection, respectively. Anti-HBs were assayed in mice sera by ELISA. HBsAg-specific CTL responses of spleen cells from immunized mice were tested by the LDH method. RESULTS Plasmids of pCI-S and pcDNA3.1-S allowed HBsAg transient expression in cell culture supernatants and cell lysates of HepG2 or COS-7 cells. Intramuscular immunization of BALB/C mice with plasmids of pCI-S or pcDNA3.1-S elicited the antibody and cytotoxic T lymphocyte responses to HBsAg. CONCLUSIONS The vectors used in this study are effective to induce prime antibody and HBsAg-specific-cytotoxic T lymphocyte responses to HBsAg in mice after intramuscular immunization.
Collapse
MESH Headings
- Animals
- COS Cells
- Cloning, Molecular
- DNA, Viral/genetics
- Eukaryotic Cells/metabolism
- Female
- Gene Expression
- Hepatitis B/immunology
- Hepatitis B/prevention & control
- Hepatitis B Surface Antigens/genetics
- Hepatitis B Surface Antigens/immunology
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Humans
- Immunization
- Mice
- Mice, Inbred BALB C
- Plasmids/genetics
- T-Lymphocytes, Cytotoxic/immunology
- Transfection
- Tumor Cells, Cultured
- Vaccines, DNA/genetics
- Vaccines, DNA/immunology
- Viral Vaccines/genetics
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- Zengwei Liang
- Institute for Viral Hepatitis, Chongqing Medical University, Chongqing 400010, China
| | | | | | | | | |
Collapse
|
27
|
Wernery U, Joseph S, Kinne J. An attenuated herpes vaccine may protect Gyr hybrids from fatal inclusion body hepatitis. A preliminary report. J Vet Med B Infect Dis Vet Public Health 2001; 48:727-32. [PMID: 11846017 DOI: 10.1046/j.1439-0450.2001.00490.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Four Gyr hybrids were used for this falcon herpes vaccine experiment. Three falcons were given 1 ml of an attenuated falcon herpesvirus vaccine (DuFaHe) subcutaneously twice within 14 days, whereas the fourth falcon was used as a control. Eighteen days after the booster vaccination, all four Gyr hybrids were intranasally and ocularly challenged with a virulent low-passage falcon herpesvirus. The control falcon died 9 days after challenge with typical lesions of herpesvirus inclusion body hepatitis. The three vaccinated falcons seroconverted and did not show any symptoms. Following the challenge their antibody titres to falcon herpesvirus increased. No herpesvirus was isolated from any of the cloacal swabs taken during this experiment, indicating that there was no danger for any other birds from DuFaHe. This experiment shows that falcons can be protected from herpesvirus infection by an attenuated herpesvirus vaccine. However, it should be stressed that only four falcons were used for this experiment.
Collapse
Affiliation(s)
- U Wernery
- Central Veterinary Research Laboratory, Dubai, United Arab Emirates
| | | | | |
Collapse
|
28
|
Orcutt RP, Phelan RS, Geistfeld JG. Exclusion of mouse hepatitis virus from a filtered, plastic rodent shipping container during an in transit field challenge. Contemp Top Lab Anim Sci 2001; 40:32-5. [PMID: 11451393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Although leading suppliers of laboratory mice and rats continue to use filtered shipping boxes to protect their animals from contamination during transport to the end user, no information had been available in the literature to demonstrate that any of these boxes actually accomplish this task. To test this hypothesis, 12 plastic shipping boxes with filters and tight-fitting lids and six cardboard shipping boxes without filters (controls) were each stocked with adult, adventitious disease-free mice. All 18 shipping boxes were transported to a facility housing a breeding colony of mice enzootically infected with four murine viruses, including mouse hepatitis virus (MHV), and were placed inside the colony for 15 h. The boxes were then transported to a commercial testing laboratory, at which the animals were aseptically removed and were held in microisolation cages for 28 days, after which their sera tested for antibody to all four murine viruses. All serum samples from mice held in the control boxes were positive for antibody to MHV, whereas sera from all mice held in filtered boxes were negative for antibody to any of the four viruses. This study demonstrates that at least one type of filtered shipping container protects mice from a field challenge of MHV. To the best of our knowledge, this is the first documentation of any microbial efficacy testing conducted on filtered shipping containers for laboratory animals.
Collapse
Affiliation(s)
- R P Orcutt
- Biomedical Research Associates, 7192 West Sundown Court, Frederick, Maryland 21702, USA
| | | | | |
Collapse
|
29
|
Aurisicchio L, Delmastro P, Salucci V, Paz OG, Rovere P, Ciliberto G, La Monica N, Palombo F. Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J Virol 2000; 74:4816-23. [PMID: 10775620 PMCID: PMC112004 DOI: 10.1128/jvi.74.10.4816-4823.2000] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/1999] [Accepted: 02/04/2000] [Indexed: 01/12/2023] Open
Abstract
The current therapy for hepatitis B and C is based on systemic administration of recombinant human alpha interferon (r-hIFN-alpha). However, systemic delivery of r-hIFN-alpha is associated with severe side effects, but more importantly, it is effective in only a small percentage of patients. In an effort to maximize IFN-alpha antiviral efficacy, we have explored the therapeutic potential of murine IFN-alpha2 (mIFNalpha2) selectively expressed in the liver. To this end, we have developed a helper-dependent adenovirus vector (HD) containing the mIFN-alpha2 gene under the control of the liver-specific transthyretin promoter (HD-IFN). Comparison with a first-generation adenovirus carrying the same mIFN-alpha2 expression cassette indicates that at certain HD-IFN doses, induction of antiviral genes can be achieved in the absence of detectable circulating mIFN-alpha2. Challenge of injected mice with mouse hepatitis virus type 3 showed that HD-IFN provides high liver protection. Moreover, liver protection was also observed in acute nonviral liver inflammation hepatitis induced by concanavalin A at 1 month postinfection. These results hold promise for the development of a gene therapy treatment for chronic viral hepatitis based on liver-restricted expression of IFN-alpha2.
Collapse
|
30
|
Abstract
Hydropericardium syndrome, an emerging disease of poultry, has recently been detected in some countries of Asia and America, particularly in broiler birds aged 3-6 weeks. The disease is characterized by its sudden occurrence with high mortality of up to 80% in broilers and low mortality of under 10% in layers, associated with hydropericardium. Its course is of 7-15 days under natural conditions. The causative agent is probably fowl adenovirus serotype 4, belonging to group I aviadenovirus genus of the family adenoviridae, which can be cultivated in primary cell cultures of chicken kidney and embryo liver cells. The transmission of disease occurs laterally by the oral-faecal route. The livers of affected birds show necrotic foci, and basophilic intranuclear inclusion bodies fill the entire enlarged nucleus of some of the hepatocytes. The disease can be diagnosed from its gross lesions, histopathological changes in the liver and by serological tests, such as agar gel diffusion, counter immunoelectrophoresis, indirect haemagglutination and ELISA. It has been brought under control by inactivated liver organ vaccines (0.25 ml/bird) or inactivated cell culture vaccines (10(3.5) LD50/bird) given by the subcutaneous route at 10-15 days of age. The vaccine is effective in the face of an outbreak and significantly reduces the mortality.
Collapse
Affiliation(s)
- R Chandra
- Department of Veterinary Microbiology, G.B. Pant University of Agriculture and Technology, Udham Singh Nagar, UP, India
| | | | | |
Collapse
|
31
|
Koo M, Bendahmane M, Lettieri GA, Paoletti AD, Lane TE, Fitchen JH, Buchmeier MJ, Beachy RN. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci U S A 1999; 96:7774-9. [PMID: 10393897 PMCID: PMC22137 DOI: 10.1073/pnas.96.14.7774] [Citation(s) in RCA: 105] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Hybrids of tobacco mosaic virus (TMV) were constructed with the use of fusion to the coat protein peptides of 10 or 15 amino acids, containing the 5B19 epitope from the spike protein of murine hepatitis virus (MHV) and giving rise to TMV-5B19 and TMV-5B19L, respectively. The TMV hybrids were propagated in tobacco plants, and the virus particles were purified. Immunogold labeling, with the use of the monoclonal MAb5B19 antibody, showed specific decoration of hybrid TMV particles, confirming the expression and display of the MHV epitope on the surface of the TMV. Mice were immunized with purified hybrid viruses after several regimens of immunization. Mice that received TMV-5B19L intranasally developed serum IgG and IgA specific for the 5B19 epitope and for the TMV coat protein. Hybrid TMV-5B19, administered by subcutaneous injections, elicited high titers of serum IgG that was specific for the 5B19 epitope and for coat protein, but IgA that was specific against 5B19 was not observed. Mice that were immunized with hybrid virus by subcutaneous or intranasal routes of administration survived challenge with a lethal dose (10 x LD50) of MHV strain JHM, whereas mice administered wild-type TMV died 10 d post challenge. Furthermore, there was a positive correlation between the dose of administered immunogen and protection against MHV infection. These studies show that TMV can be an effective vaccine delivery vehicle for parenteral and mucosal immunization and for protection from challenge with viral infection.
Collapse
MESH Headings
- Administration, Intranasal
- Amino Acid Sequence
- Animals
- Epitopes/administration & dosage
- Epitopes/immunology
- Female
- Hemagglutinins, Viral/administration & dosage
- Hemagglutinins, Viral/immunology
- Hepatitis B Vaccines
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Immunization Schedule
- Injections, Subcutaneous
- Membrane Glycoproteins/administration & dosage
- Membrane Glycoproteins/immunology
- Mice
- Mice, Inbred BALB C
- Murine hepatitis virus/immunology
- Spike Glycoprotein, Coronavirus
- Tobacco Mosaic Virus/immunology
- Vaccines, Synthetic
- Viral Envelope Proteins/administration & dosage
- Viral Envelope Proteins/immunology
- Viral Hepatitis Vaccines
Collapse
Affiliation(s)
- M Koo
- Department of Cell Biology, Division of Plant Biology, BCC 206, La Jolla, CA 92037, USA
| | | | | | | | | | | | | | | |
Collapse
|
32
|
See DM, Tilles JG. Occurrence of coxsackievirus hepatitis in baby rabbits and protection by a formalin-inactivated polyvalent vaccine. Proc Soc Exp Biol Med 1997; 216:52-6. [PMID: 9316610 DOI: 10.3181/00379727-216-44155] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
It was observed that 23-day-old New Zealand white rabbits came down with acute hepatitis demonstrable 3 days after intraperitoneal injection with 12 coxsackievirus group B strains. The model was used to evaluate a polyvalent, formalin-inactivated virus vaccine prepared with prototype strains of coxsackievirus groups B1-6. Seven-day-old animals received one intraperitoneal and two subcutaneous injections containing the vaccine or placebo. The regimen was repeated at 15 days of age. At 23 days of age, groups of rabbits were challenged with 1 x 10(5) plaque-forming units of a clinical strain of group B coxsackievirus and sacrificed 3 days later. The mean neutralizing antibody titer for the 12 strains tested (log2) was 4.5 +/- 1.0 eight days after the second dose of vaccine. In vaccinated animals, elevated liver function tests in the serum, and titer of virus and histopathologic abnormalities in the liver were significantly reduced for each strain tested compared with infected, unvaccinated controls. Cultures of the heart, skeletal muscle, pancreas, blood, and spleen were all negative. Thus, clinical strains of coxsackie group B viruses produced isolated hepatitis in baby rabbits. Prophylaxis with a polyvalent, inactivated-virus vaccine significantly reduced the severity of liver involvement for all 12 clinical strains tested.
Collapse
Affiliation(s)
- D M See
- Department of Medicine, University of California Irvine Medical Center, Orange 92668, USA
| | | |
Collapse
|
33
|
Uetsuka K, Suzuki M, Kai C, Goto N. Protective effects of a novel quinone derivative, E3330, on mouse hepatitis virus (MHV)-induced chronic hepatitis in athymic nude mice. Exp Anim 1997; 46:219-23. [PMID: 9250483 DOI: 10.1538/expanim.46.219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
In this experiment, we examined the protective effects of a novel quinone derivative, E3330, on MHV-2cc-induced chronic hepatitis in athymic nude mice for up to 3 weeks after virus infection. The daily dose of 25 mg/kg b.w. suppressed the viral replication in the liver and the progression of hepatic lesions. The expansion of small focal lesions at 1 week after viral inoculation (WAI) was suppressed at 2 WAI, and the lesions were still small at 3 WAI in E3330-administered group, whereas small focal lesions at 1 WAI were expanded at 2 WAI to fuse with each other at 3 WAI in the control group. E3330 therefore showed protective effects on MHV-2cc-induced chronic hepatitis in athymic nude mice, but further studies are needed to analyze the mechanism.
Collapse
Affiliation(s)
- K Uetsuka
- Department of Veterinary Pathology, Faculty of Agriculture, University of Tokyo, Japan
| | | | | | | |
Collapse
|
34
|
Uetsuka K, Nakayama H, Goto N. Protective effect of recombinant interferon (IFN)-alpha/beta on MHV-2cc-induced chronic hepatitis in athymic nude mice. Exp Anim 1996; 45:293-7. [PMID: 8840151 DOI: 10.1538/expanim.45.293] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The protective effects of recombinant IFN-alpha/beta on MHV-2cc-induced chronic and persistent hepatitis in athymic nude mice were examined. The mice intraperitoneally (ip) inoculated with MHV-2cc at day 0 of experiment were divided into 4 groups. Three of them were administered ip with recombinant IFN-alpha/beta at a daily dose of 1 x 10(3) IU from -1 (-1D-group), 0 (0D-group), and +1 day of experiment (+1D-group), respectively, for 3 consecutive weeks. The remaining one (control group) was given 0.1 ml/mouse of PBS from +1 day of the experiment in the same way. Three mice in each group were killed at 1, 2 and 3 weeks post inoculation (WPI) with MHV, respectively. The liver virus titer in the control group increased gradually and maintained high levels throughout the experimental period. In the IFN-groups, particularly in the -1D- and 0D-groups, the virus titers were significantly lower than that in control group. Histopathologically, focal hepatic lesions were observed at 1WPI and large irregular inflammatory lesions developed at 3WPI in the control group. Similar but somewhat less severe lesions were observed in the +1D-group. In the -1D- and 0D-groups, lesions were not observed at 1WPI and only small organized lesions with mononuclear cell infiltration were seen at 3WPI. In conclusion, it was clarified in the present study that the progression of MHV-2cc-induced chronic hepatitis in athymic nude mice was effectively prevented by extrinsic IFN-alpha/beta when administered from -1 day and 0 day of the virus infection.
Collapse
Affiliation(s)
- K Uetsuka
- Department of Veterinary Pathology, Faculty of Agriculture, University of Tokyo, Japan
| | | | | |
Collapse
|
35
|
Pope M, Chung SW, Mosmann T, Leibowitz JL, Gorczynski RM, Levy GA. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection. J Immunol 1996; 156:3342-9. [PMID: 8617959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Murine hepatitis virus strain 3 (MHV-3) produces a strain-dependent spectrum of disease. The development of liver necrosis has been shown to be related to production of a unique macrophage procoagulant activity (PCA), encoded by the gene fgl-2, in susceptible mice. These studies were designed to examine the influence of Th1/Th2 cells on resistance/susceptibility and production of macrophage PCA in resistant (A/J) and susceptible (BALB/cJ) strains of mice following infection with MHV-3. Immunization of A/J mice with MHV-3 induced a Th1 cellular immune response, and one Th1 cell line (3E9.1) protected susceptible mice and inhibited PCA production by macrophages both in vitro and in vivo. In contrast, immunization of BALB/cJ mice with an attenuated variant of MHV-3 derived from passaging MHV-3 in YAC-1 cells resulted in a Th2 response. Transfer of spleen cells and T cell lines from immunized BALB/cJ mice failed to protect naive susceptible syngeneic mice from infection with MHV-3 and augmented macrophage PCA production to MHV-3 in vitro. However, serum from immunized BALB/cJ mice contained high titrated neutralizing Ab that protected naive BALB/cJ animals from lethal primary MHV-3 infection. These results demonstrate that susceptible BALB/cJ mice generate a Th2 response following MHV-3 infection and that these Th2 cells neither inhibit MHV-3-induced macrophage PCA production nor protect naive mice from MHV-3 infection. The results suggest that Ab protects against primary infection but cannot eradicate ongoing infection. Thus, these data define the differential role of Th1/Th2 lymphocytes in primary and secondary MHV-3 infection and emphasize the importance of PCA in the pathogenesis of MHV-3 infection.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/therapeutic use
- Blood Coagulation Factors/biosynthesis
- Blood Coagulation Factors/immunology
- Cell Line
- Coronavirus Infections/immunology
- Disease Susceptibility
- Female
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Immunity, Innate
- Immunization, Passive
- Immunotherapy, Adoptive
- Macrophages/immunology
- Mice
- Mice, Inbred A
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Murine hepatitis virus/immunology
- Spleen/transplantation
- Th1 Cells/immunology
- Th1 Cells/virology
- Th2 Cells/immunology
- Th2 Cells/virology
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- M Pope
- Department of Surgery, The Toronto Hospital-University of Toronto, Ontario, Canada
| | | | | | | | | | | |
Collapse
|
36
|
Lamarre A, Talbot PJ. Protection from lethal coronavirus infection by immunoglobulin fragments. J Immunol 1995; 154:3975-84. [PMID: 7706736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Molecular mechanisms of in vitro and in vivo virus neutralization by specific Ab remain largely undefined. Murine coronaviruses provide an excellent animal model for such studies. To determine the role of Ab bivalency and the contribution of its Fc portion in the neutralization of viral infectivity and passive protection of mice by an in vitro neutralizing and in vivo protective mAb (7-10A), F(ab')2 and Fab fragments were generated and their biologic properties were examined. The two fragments reacted in ELISA like the whole Ab against viral Ag or specific anti-idiotypic Abs. The affinity constants of the different Ab preparations were determined by surface plasmon resonance using immobilized anti-idiotypic Abs. The apparent affinity constant of the whole Ab molecule was 7.0 x 10(9) M-1 and was reduced 2-fold for F(ab')2 fragments and 14-fold for Fab molecules. Like whole Ab, both F(ab')2 and Fab fragments could neutralize virus in vitro and passively protect mice in vivo. However, the efficiency of in vivo neutralization by Fab fragments was reduced compared with the bivalent molecules, despite almost identical half-lives of both types of Ab fragments. These results demonstrate that in vitro and in vivo virus neutralization mechanisms by this Ab are independent of Fc-mediated functions and bivalency, but are probably influenced by Ab avidity. Also, this is the first report of in vivo protection against a viral infection by Fab fragments of antiviral Ab.
Collapse
MESH Headings
- Animals
- Antibodies, Anti-Idiotypic/immunology
- Antibodies, Monoclonal/immunology
- Coronavirus Infections/immunology
- Coronavirus Infections/prevention & control
- Encephalitis, Viral/prevention & control
- Female
- Hepatitis Antibodies/immunology
- Hepatitis, Viral, Animal/immunology
- Hepatitis, Viral, Animal/prevention & control
- Immunization, Passive
- Immunoglobulin Fab Fragments/metabolism
- Immunoglobulin Fab Fragments/therapeutic use
- Male
- Membrane Glycoproteins/immunology
- Metabolic Clearance Rate
- Mice
- Mice, Inbred BALB C
- Murine hepatitis virus/immunology
- Neutralization Tests
- Spike Glycoprotein, Coronavirus
- Viral Envelope Proteins/immunology
Collapse
Affiliation(s)
- A Lamarre
- Virology Research Center, Armand-Frappier Institute, University of Quebec, Laval, Canada
| | | |
Collapse
|
37
|
Abstract
The effect of suramin on duck hepatitis B virus (DHBV) infection was investigated in vivo. Suramin pretreatment of Pekin ducklings completely prevented DHBV infection. In contrast, suramin given at the time of or after inoculation with DHBV did not inhibit viral infection, replication, or gene expression. These data indicate that suramin effectively blocks the early stages of DHBV infection in vivo.
Collapse
|
38
|
Munshi A, Mehrotra R, Panda SK. Evaluation of Phyllanthus amarus and Phyllanthus maderaspatensis as agents for postexposure prophylaxis in neonatal duck hepatitis B virus infection. J Med Virol 1993; 40:53-8. [PMID: 8515247 DOI: 10.1002/jmv.1890400111] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The therapeutic potential of plant extracts of Phyllanthus amarus and Phyllanthus maderas patensis for postexposure prophylaxis against infection by Hepadnaviruses was studied in ducklings infected by the duck hepatitis B virus (DHBV). Forty-four Pekin ducklings were inoculated intraperitoneally with DHBV at 24 hr post-hatch. They were treated by intraperitoneal injection of Phyllanthus amarus (aqueous extract) (100 mg/kg body weight) or Phyllanthus mad eraspatensis (alcoholic extract) (100 mg/kg body weight) for a period of 4 weeks. Infected ducklings treated with saline served as controls. Weekly serum samples obtained before, during, and after treatment were analysed for the presence of DHBV DNA in serum by dot blot hybridisation using alpha 32P-labelled probes. Liver tissue was collected after killing the ducks at various time intervals and was studied for replicative status of the viral DNA and liver histopathology; 17 of 21 ducks were viraemic on completion of treatment with Phyllanthus amarus. At 16 week posttreatment follow-up four of seven animals remained viraemic. Similar results were obtained with Phyllanthus maderaspatensis. There was no alteration in DHBV replication in the liver. No toxicity was observed with this treatment. These observations suggest that Phyllanthus amarus and Phyllanthus maderaspatensis are not useful as therapeutic agents for postexposure prophylaxis against DHBV infection.
Collapse
MESH Headings
- Animals
- Animals, Newborn
- Blotting, Southern
- DNA Probes
- DNA, Viral/blood
- DNA, Viral/isolation & purification
- Disease Models, Animal
- Ducks
- Hepatitis B Virus, Duck/drug effects
- Hepatitis B Virus, Duck/genetics
- Hepatitis, Viral, Animal/diagnosis
- Hepatitis, Viral, Animal/prevention & control
- Immunoblotting
- Lethal Dose 50
- Liver/microbiology
- Plant Extracts/therapeutic use
- Plant Extracts/toxicity
- Plants, Medicinal/chemistry
- Time Factors
- Viremia/drug therapy
Collapse
Affiliation(s)
- A Munshi
- Department of Pathology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi
| | | | | |
Collapse
|
39
|
Abstract
Two isolator caging systems were evaluated against challenge with MHV-Y, an enterotropic strain of mouse hepatitis virus. The systems were similar in that they both used an identical shoebox cage equipped with a polycarbonate filter top incorporating a Reemay filter. They differed in that one system supplied HEPA-filtered air through a grommet in the filter lid so that the cage was pressurized slightly. A rack holding 60 cages (30 front and back) was utilized. Thirty cages without filter tops housed one mouse each that had been infected orally with 19,000 ID50 of MHV-Y and an uninfected cagemate. The remaining 30 cages, each housing 2 uninfected mice were divided into 3 groups of 10 cages. Group I cages (controls) had no filter top; Group II cages were equipped with filter tops; and Group III were equipped with filter tops and intracage HEPA-filtered air. The cages housing uninfected mice were interspersed between, above, below and behind cages housing infected mice. The uninfected mice were maintained in contact with the MHV-Y infected mice for 8 weeks. Transmission of MHV-Y was determined serologically by indirect ELISA. All mice housed within the Group I cages (control) seroconverted to MHV, while only 4 mice (2 cages) seroconverted in Group II, and no mice seroconverted in Group III.
Collapse
Affiliation(s)
- N S Lipman
- Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge 02139
| | | | | |
Collapse
|
40
|
Schödel F, Neckermann G, Peterson D, Fuchs K, Fuller S, Will H, Roggendorf M. Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection. Vaccine 1993; 11:624-8. [PMID: 8322485 DOI: 10.1016/0264-410x(93)90307-j] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Woodchucks were immunized with recombinant woodchuck hepatitis virus (WHV) nucleocapsid antigen (WHcAg) or hepatitis B virus (HBV) nucleocapsid antigen (HBcAg) and challenged with 10(6) WHV ID50. Six out of six woodchucks immunized with WHcAg and four out of six immunized with HBcAg were protected from WHV infection. Woodchucks immunized with WHcAg or HBcAg developed high serum antibody titres against WHcAg or HBcAg. Antibodies against WHc and HBc displayed little cross-reactivity (< 1%). This confirms and extends previous reports of protection against homologous challenge after immunization with HBcAg/WHcAg which are both internal viral antigens. As the dominant B-cell epitope(s) on particulate WHcAg and HBcAg appear not to be conserved it also demonstrates that antibodies against HBcAg/WHcAg are not important for this protection. Woodchucks immunized with WHcAg/HBcAg reacted with a fast serum antibody response against viral envelope proteins upon challenge with WHV, indicative of functional intrastructural/intermolecular T-cell help as one potential mechanism of protection after immunization with an internal viral antigen.
Collapse
Affiliation(s)
- F Schödel
- Max-Planck-Institut für Biochemie, Martinsried, Germany
| | | | | | | | | | | | | |
Collapse
|
41
|
Eckart MR, Dong C, Houghton M, D'Urso N, Ponzetto A. The effects of using recombinant vaccinia viruses expressing either large or small HDAg to protect woodchuck hepadnavirus carriers from HDV superinfection. Prog Clin Biol Res 1993; 382:201-205. [PMID: 8502680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Live rVVs expressing either p24 delta or p27 delta were produced and used to immunize woodchuck hepadnavirus carriers. Upon challenge with infectious HDV, circulating HDV RNA levels appeared to be similar in both controls and vaccinees. Although extended follow-up studies of these animals is necessary before making firm conclusions, including an analysis of circulating HDAg levels, these preliminary results provide no evidence for a protective immunity conferred by the rVVs. In contrast, we have shown in other studies that repeated immunization of woodchucks with purified, recombinant p24 delta subunit does confer significant protection against HDV challenge in some of the vaccinees (A. Ponzetto, et al., this volume). The underlying immunological mechanisms responsible for the different outcome of these varied vaccination regimens remain to be elucidated.
Collapse
Affiliation(s)
- M R Eckart
- Chiron Corporation, Emeryville, CA 94608
| | | | | | | | | |
Collapse
|
42
|
Li C, Fung LS, Chung S, Crow A, Myers-Mason N, Phillips MJ, Leibowitz JL, Cole E, Ottaway CA, Levy G. Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection. J Exp Med 1992; 176:689-97. [PMID: 1324969 PMCID: PMC2119354 DOI: 10.1084/jem.176.3.689] [Citation(s) in RCA: 59] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
The induction of monocyte/macrophage procoagulant activity (PCA) has been implicated in the pathogenesis of murine hepatitis virus strain 3 (MHV-3) infection and disease. Previously, we have shown that induction of PCA by MHV-3 correlated with resistance/susceptibility to infection in different mouse strains. In this study, all BALB/cJ mice that were infected with 10(3) plaque-forming units of MHV-3 developed severe liver disease and died within 96-120 h. Examination of the livers of these animals showed marked hepatic necrosis, deposition of fibrin, and cellular expression of PCA by direct immunofluorescence staining in areas of necrosis as well as in hepatic sinusoids. Splenic mononuclear cells recovered from these mice expressed high concentrations of PCA with time after infection. Infusion into mice of a high-titered monoclonal antibody that neutralized PCA (3D4.3) attenuated the development of hepatic necrosis and enhanced survival in a dose-dependent manner. All of the animals receiving 100 micrograms, and 44% and 22% of the animals that received 50 and 25 micrograms per day, respectively, survived for 10 d and made a full recovery. Administration of the antibody resulted in a dose-dependent reduction in fibrin deposition, PCA expression as detected by direct immunofluorescence staining and by a functional assay. In animals treated with high concentrations of antibody, titers of antibody to PCA fell from 87 +/- 15 micrograms/ml to 100 +/- 7 ng/ml during the active phase of the disease, consistent with sequestration due to binding of the immunoglobulin to cells expressing PCA. Surviving animals, when rechallenged with MHV-3, had a 40% mortality, consistent with the known rates of metabolism of immunoglobulin. This further suggested that protection was by a passive mechanism. The results reported here demonstrate that a neutralizing antibody to PCA protects animals from fulminant hepatitis and death associated with MHV-3 infection, and supports the notion that PCA is a potent inflammatory mediator that plays a pivotal role in the pathogenesis of liver injury resulting from MHV-3 infection.
Collapse
Affiliation(s)
- C Li
- Department of Medicine, University of Toronto, Canada
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Lamarre A, Lecomte J, Talbot PJ. Antiidiotypic vaccination against murine coronavirus infection. J Immunol 1991; 147:4256-62. [PMID: 1661313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Rabbit polyclonal antiidiotypic antibodies were generated against a neutralizing mAb specific for a conformational epitope on the S glycoprotein of murine hepatitis virus, strain A59 (MHV-A59). These anti-Id were directed predominantly against an Id that was undetectable in rabbit and rat anti-MHV-A59 sera and weakly represented in syngeneic and allogeneic antiviral sera. However, some partial idiotypic sharing was observed between the Id-bearing antibody and a mAb with a similar antigenic site specificity. The anti-Id inhibited the virus-binding and neutralizing activities of the immunizing antibody, demonstrating that they recognize paratope-associated idiotopes. Mice immunized with affinity-purified anti-Id developed MHV-A59-specific antibodies that neutralized viral infectivity to high titers. Moreover, these animals survived an otherwise lethal challenge with viral murine hepatitis virus, unlike control mice immunized with normal rabbit Ig. These results indicate that at least a subpopulation of the polyclonal anti-Id could induce a protective immune response directed toward a biologically important MHV-A59 epitope, and demonstrate the feasibility of antiidiotypic vaccination against a coronavirus infection.
Collapse
Affiliation(s)
- A Lamarre
- Virology Research Center, Université du Québec, Laval, Canada
| | | | | |
Collapse
|
44
|
Offensperger WB, Offensperger S, Walter E, Blum HE, Gerok W. Sulfated polyanions do not inhibit duck hepatitis B virus infection. Antimicrob Agents Chemother 1991; 35:2431-3. [PMID: 1804020 PMCID: PMC245399 DOI: 10.1128/aac.35.11.2431] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
On the basis of the antiviral action of sulfated polyanions in human immunodeficiency virus and other viral infections, we studied the effect of dextran sulfate and heparin on duck hepatitis B virus infection. These agents do not affect viral uptake and replication in liver cells in vitro or in vivo. Sulfated polyanions, therefore, appear to have no potential for the treatment of hepadnavirus infections.
Collapse
|
45
|
Abstract
The early phases of hepadnaviral infection were studied in primary duck hepatocyte cultures. Incubation of duck hepatocytes in vitro with duck hepatitis B virus (DHBV) resulted in infection with high levels of viral replication. The lysosomotropic agents ammonium chloride and chloroquine effectively inhibited viral infection, indicating that DHBV infection, similar to infection with other enveloped viruses, depends on receptor-mediated endocytosis and involves membrane fusion triggered by low pH.
Collapse
|
46
|
Argüello Villares JL. Viral haemorrhagic disease of rabbits: vaccination and immune response. REV SCI TECH OIE 1991; 10:459-80. [PMID: 1760586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Results are presented for the large-scale use of a tissue vaccine, inactivated with beta-propiolactone and containing aluminium hydroxide adjuvant, against viral haemorrhagic disease of rabbits. The kinetics of haemagglutination-inhibiting antibodies over eighteen months, the response of vaccinated animals to challenge infection with field virus between six and fifteen months after vaccination, the serological response to revaccination, and the immunological mechanisms involved in primary vaccination and revaccination were investigated.
Collapse
|
47
|
Rodák L, Smíd B, Valícek L. Application of control measures against viral haemorrhagic disease of rabbits in the Czech and Slovak Federal Republic. REV SCI TECH OIE 1991; 10:513-24. [PMID: 1760589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The first outbreaks of viral haemorrhagic disease (VHD) of rabbits were reported from eastern Slovakia in 1987. In 1988, the infection spread throughout the Czech and Slovak Federal Republic. Electron microscopy was used by the Veterinary Research Institute in Brno to diagnose the disease during the early stage of infection. At present, the regional laboratories of the veterinary investigation services use the haemagglutination and the direct immunofluorescence tests as the principal methods to demonstrate the causal agent. Indirect immunofluorescence and immunoperoxidase techniques have been developed to demonstrate VHD virus, while the enzyme-linked immunosorbent assay (ELISA) has been used to detect antibodies. Diagnostic kits, allowing a wide use of these methods, are now available commercially. Two types of inactivate vaccines were developed and produced in 1988 and 1989. VHD is controlled by vaccination of exposed rabbit colonies. This is accompanied by other preventive and protective measures, directed by district veterinary officers following instructions from federal authorities.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/blood
- Czechoslovakia/epidemiology
- Hepatitis, Viral, Animal/diagnosis
- Hepatitis, Viral, Animal/epidemiology
- Hepatitis, Viral, Animal/prevention & control
- Rabbits
- Vaccination/veterinary
- Vaccines, Inactivated
- Viral Vaccines
- Viruses, Unclassified/immunology
- Viruses, Unclassified/ultrastructure
Collapse
Affiliation(s)
- L Rodák
- Veterinary Research Institute, Brno, Czech and Slovak Federal Republic
| | | | | |
Collapse
|
48
|
Cancellotti FM, Renzi M. Epidemiology and current situation of viral haemorrhagic disease of rabbits and the European brown hare syndrome in Italy. REV SCI TECH OIE 1991; 10:409-22. [PMID: 1662099 DOI: 10.20506/rst.10.2.558] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Rabbit production is of considerable economic importance in Italy. In the last thirty years, meat production has risen and the number of intensive husbandry establishments has grown. The major region of production (about 60%) lies in the northern part of the country. In addition, approximately one million live animals and more than 14,000 tons of meat are imported yearly. More than 150,000 hares are also imported for restocking and hunting purposes. During the second half of the 1980s a "new" disease (X disease), characterised by haemorrhagic and degenerative lesions and high mortality, was observed on traditional farms in some regions. This form spread throughout the country between 1986 and 1988. In 1988, diagnostic research led to identification of a viral agent. Because of its morphology, the virus was at first considered a picornavirus. More recent research has included the virus in the Caliciviridae family. This agent reproduces the disease experimentally. Between 1988 and 1989, many intensive establishments in several regions were affected by the disease, known as viral haemorrhagic disease (VHD); the losses were always very high. In 1989, after mortality among free-living hares had been observed in the northern part of Italy for some years, the agent of the European brown hare syndrome (EBHS) was identified as being morphologically similar to the VHD virus. The antigenic relationship between VHD and EBHS and the possibility of cross-infection between rabbits and hares are currently being studied. Hygienic measures and vaccination are the most reliable methods of control. International cooperation has greatly helped in the study of the disease and in the adoption of control measures.
Collapse
Affiliation(s)
- F M Cancellotti
- Istituto Zooprofilattico Sperimentale delle Venezie, Padua, Italy
| | | |
Collapse
|
49
|
Huang HB. Vaccination against and immune response to viral haemorrhagic disease of rabbits: a review of research in the People's Republic of China. REV SCI TECH OIE 1991; 10:481-98. [PMID: 1760587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Viral haemorrhagic disease (VHD) of rabbits is an acute entity with high mortality which affects adult rabbits. Several vaccines have been developed in China and extensive use of these vaccines in the field has controlled the spread of the disease. Formalin inactivated tissue vaccine induces solid immunity on the third to fourth day post vaccination and immunity lasts for at least six months. The oil-emulsion tissue vaccine which has been developed has longer lasting potency. Successful adaptation of VHD virus (VHDV) to cultured cells and preliminary immunisation will provide the possibility of large-scale production of cell-cultured virus vaccine. Passive, emergency immunisation with hyperimmune antiserum provides short-term protection of threatened rabbits as well as treatment of infected rabbits in the field. Histopathological and pathophysiological studies reveal that immune cells and organs are the most affected targets in infected rabbits; owing to the damage to the endothelial system of blood vessels, extensive disseminated intravascular coagulation (DIC) occurs in the parenchymal tissues. Destruction of the immune system and the occurrence of DIC lead to acute illness and sudden death post infection. Experimental immunological studies demonstrate that the induction of rapid immunity is coordinated by macrophages and T and B lymphocytes in the initial, post-immunisation stage, whereas humoral immunity plays the main role in long-term protection against VHDV infection. The positive association of post-vaccination protection with haemagglutination inhibition antibody can also be observed. Interferon probably takes effect as an anti-VHDV agent soon after vaccination.
Collapse
Affiliation(s)
- H B Huang
- National Institute for the Control of Veterinary Bioproducts and Pharmaceuticals, Ministry of Agriculture, Beijing, People's Republic of China
| |
Collapse
|
50
|
Löliger HC, Eskens U. Incidence, epizootiology and control of viral haemorrhagic disease of rabbits and the European brown hare syndrome in Germany. REV SCI TECH OIE 1991; 10:423-34. [PMID: 1662100 DOI: 10.20506/rst.10.2.557] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Viral haemorrhagic disease (VHD) among domestic and wild rabbits and European brown hares have been observed in most of the Federal states of Germany. Acute outbreaks of viral haemorrhagic disease are most prevalent in small, fancy domestic rabbitries, with mortality varying between 5 and 90%, while mostly sporadic losses due to VHD are seen among wild rabbits. In hares, accumulated losses from the European brown hare syndrome (EBHS) can occasionally be observed in areas where fresh green feed, such as young O.O-rape plants, is available. VHD of rabbits and EBHS are caused by calicivirus strains. The natural virus reservoirs are wild rabbit and hare populations. Mutual infection of rabbits and hares seems to be possible. Transmission and spread of infectious virus occurs by direct contact of animals, or indirectly by contaminated excrement, green feed or living vectors. Calicivirus infections are widespread in several states, with accumulation of losses among domestic and wild rabbits by VHD, or in hares by EBHS, within certain areas. Disease hygiene, together with vaccination, are the officially preferred control measures in domestic rabbitries.
Collapse
Affiliation(s)
- H C Löliger
- Institute for Poultry and Small Animal Research, Federal Agricultural Research Centre, Celle, Germany
| | | |
Collapse
|